FOXO1 and neoplasm: With IL-2 and resveratrol co-treatment, the expression levels of FoxO1 were not different from the resveratrol treatment alone (Fig. 9C), which suggest that IL-2 does not directly affect the expression of FoxO1 in B16F10 tumor cells.